Global Analysis of Adequacy of Prescription Opioid Consumption across 214 Countries and Territories

Global Adequacy of Prescription Opioids

Shirish Rao MBBS Student[1,2], Siddhesh Zadey BSMS MScGH[1,3,4]

1 Association for Socially Applicable Research (ASAR), Pune, Maharashtra, India
2 Seth G.S. Medical College and K.E.M. Hospital, Mumbai, Maharashtra, India
3 Department of Surgery, Duke University School of Medicine, Durham NC USA
4 Dr. D.Y. Patil Medical College, Hospital, and Research Centre, Pune, Maharashtra, India

Correspondence: Siddhesh Zadey, BSMS MSc-GH; ASAR Office Address: D2 Sai Heritage, New DP Road, Aundh, Pune, Maharashtra, India 411007; Email: sidzadey@asarforindia.org; Ph. No.: +1-919-699-9557

Type of article: Research Letter

Word Count: 1006

Author Contributions:

Shirish Rao: Conceptualization, Methodology, Formal Analysis, Data Curation, Writing - Original Draft, Review & Editing.

Siddhesh Zadey: Conceptualization, Methodology, Visualizations, Writing - Original Draft, Writing - Review & Editing, Supervision, Project Administration.

Funding: No funding was received for conducting this study.

Acknowledgments: None.

Competing interests: The authors have no relevant financial or non-financial interests to disclose.

Ethics approval and consent to participate: Not applicable

Consent for publication: Not applicable

Availability of data and materials: All data used and produced in the manuscript has been included in the supplement.

Abstract

Background: Inadequate access to pain management has consequences for perioperative care. Access to perioperative care globally is critical for equitable surgical, obstetric, trauma, and anesthesia (SOTA) care. Adequacy of prescription opioid consumption (AOC) can fill this gap. This study aimed to use the AOC index to assess global adequacy using recent data across 214 countries and territories, World Health Organization (WHO) regions, and World Bank Income Groups (WBIGs).

Methods: We conducted a cross-sectional retrospective analysis using data on prescription opioid consumption for 214 countries and territories using previously published data for 2017. Country-wise data on the mean annual consumption of all prescription opioids were obtained in milligrams per capita. For adequacy, AOC normative threshold was calculated as the arithmetic mean of prescription opioid consumption of twenty countries with the topmost HDI values as of 2017. Country-wise AOC index was calculated as the country's mean annual prescription opioid consumption divided by the threshold and the fraction multiplied by a hundred. The adequacy levels were classified as adequate (AOC >100), moderate (<100 and >30), low (<30 and >10), very low (<10 and >3), and extremely (<3). AOC was also calculated for WBIGs (as of 2017) and WHO regions. AOC values across WBIGs and WHO regions were compared using Welch's Analysis of Variance (ANOVA) tests. Post-hoc pairwise comparisons were conducted using the Games-Howell test with Holm Bonferroni correction for multiple comparisons. A conventional significance level of 5% was used for all tests. Analysis was conducted in Google Sheets, JAMOVI, and RStudio.

Results: The average prescription opioid consumption of the top twenty HDI countries was found to be 172.8 mg/capita annually. Across countries, AOC index values ranged from 279.23 for Germany to 0.0012 for Angola. Merely 4.21% of the 214 countries and territories had an adequate level of consumption of prescription opioids. 6.54% of countries had moderate, 10.75% had low, 18.69% had very low, and a staggering 59.81% of countries had extremely low AOC index depicting massive differences in adequacy. 190 countries could be assigned to WHO regions and WBIGs. AOC values differed significantly across WHO regions (p<0.001). AOC values differed significantly across country income groups (p=0.001).

Conclusion: In this systematic global analysis, we find that most low- and middle-income countries (LMICs) situated in the Global South lack access to prescription opioids. A majority of LMICs fall severely short, with their AOC index <1%. Low AOC can be seen as an indicator of poor access to pain management and thereby anesthesia care. This calls for the integration of AOC in the broader SOTA care indicators.

Introduction

Prescription opioids are crucial in providing effective pain management during surgical procedures and in the perioperative period. Inadequate pain control can worsen patient outcomes, including delayed recovery, increased risk of infection, and prolonged hospital stays [1]. Access to opioid analgesics is crucial for anesthetists to minimize risks involved in pain management and ensure safe patient care which can be proxied through consumption. Hence, prescription opioid consumption is considered an important anesthesia care indicator across health systems. Previous studies have quantified the consumption of prescription opioids using global data from multiple sources [2–5]. However, consumption does not directly notify adequacy which requires determining a normative threshold. Recently, a new index called Adequacy of Opioid Consumption (AOC) was proposed [6]. The AOC index leverages the association of opioid consumption with the human development index (HDI) to set normative levels of adequacy.

Inadequate access to pain management has consequences for perioperative care [7]. Access to perioperative care globally is critical for equitable surgical, obstetric, trauma, and anesthesia (SOTA) care [8]. The Lancet Commission on Global Surgery (LCoGS) indicators did not look at anesthesia care beyond anesthetist density [9]. Adequacy of prescription opioid consumption can fill this gap as it can be an indicator proxying safe anesthesia delivery in the broader global SOTA care discourse. This study aimed to use the AOC index to assess global adequacy using recent data across 214 countries and territories, World Health Organization (WHO) regions, and World Bank Income Groups (WBIGs).

Methods

We conducted a cross-sectional retrospective analysis using data on prescription opioid consumption for 214 countries and territories using previously published data [4]. This data is taken from the International Narcotics Control Board (INCB) for 2015-2017 [10]. Prescription opioid drugs were defined as those which are prescribed for medical uses like anesthesia, pain management, antidiarrheals, cough suppressants, etc., and are controlled by the INCB. Country-wise data on the mean annual consumption of all prescription opioids were obtained in milligrams per capita. For adequacy, AOC normative threshold was calculated as the arithmetic mean of prescription opioid consumption of twenty countries with the topmost HDI values as of 2017. Country-wise AOC index was calculated as the country's mean annual prescription opioid consumption divided by the threshold and the fraction multiplied by a hundred. The adequacy levels were classified as adequate (AOC >100), moderate (<100 and >30), low (<30 and >10), very low (<10 and >3), and extremely low (<3) [6]. AOC was also calculated for WBIGs (as of 2017) and WHO regions. AOC values across WBIGs and WHO regions were compared using Welch's Analysis of Variance (ANOVA) tests. Post-hoc pairwise comparisons were conducted using the Games-Howell test with Holm Bonferroni correction for multiple comparisons. A conventional significance level of 5% was used for all tests. Analysis was conducted in Google Sheets, JAMOVI, and RStudio. All data created and used in this study are available in the Supplement.

Results

The average prescription opioid consumption of the top twenty HDI countries was found to be 172.8 mg/capita annually. AOC was calculated for 214 countries and territories as depicted in **Figure 1A** using this as a threshold. Across countries, AOC index values ranged from 279.23 for Germany to 0.0012 for Angola. Merely 4.21% of the 214 countries and territories had an adequate level of consumption of prescription opioids. 6.54% of countries had moderate, 10.75% had low, 18.69% had very low, and a staggering 59.81% of countries had extremely low AOC index depicting massive differences in adequacy. 190 countries could be assigned to WHO regions and WBIGs. AOC values differed significantly across WHO regions (p<0.001). Post-hoc tests found that AOC values were significantly higher for the European region compared to Eastern Mediterranean, Southeast Asian, and African regions **(Figure 1B)**. AOC values differed significantly across country income groups (p=0.001). Post-hoc tests revealed that AOC was significantly higher for high-income countries (HICs) compared to other groups. The difference was also significant between upper-middle-income countries (UMICs) and low-income countries (LICs) **(Figure 1C)**.

Discussion

In this systematic global analysis, we find that most low- and middle-income countries (LMICs) situated in the Global South lack access to prescription opioids. A majority of LMICs fall severely short, with their AOC index <1%. Low AOC can be seen as an indicator of poor access to pain management and thereby anesthesia care. However, it is noteworthy that the supply and consumption of opioids are also governed by country-level regulations, policies, and protocols [11]. Balancing opioid control to avoid misuse with ensuring adequate access to opioids for patient management is difficult to achieve despite collaborative efforts from anesthesia associations, medical boards, and involved policymakers [12]. Even so, prioritizing access to safe anesthesia care is critical for ensuring better perioperative outcomes in LMICs [13].

While novel, comprehensive, and valuable to global SOTA care research and policy agenda, our findings should be interpreted given the following caveats and limitations. First, we used 2017 data from a previous study as the latest (2022) INCB reports do not provide direct values for 'prescription' opioid consumption. Annual updating of AOC values using INCB reports can ensure sufficient data for monitoring and evaluation. Second, the data includes 29 countries with zero opioid consumption without clarity on whether it reflects no consumption, unreported data, or inaccurately reported data. We have included these countries under the 'extremely low' adequacy level for completeness. Third, we have used data available only on INCB. However, recent studies have used global market datasets such as IQVIA MIDAS for more granular analyses [3]. However, we did not use it to ensure greater country coverage. Fourth, we used mg/capita as the unit for opioid consumption instead of commonly used morphine milliequivalents or defined daily dose, owing to available data. However, AOC is a ratio and has no units. Future research needs to correct some of these limitations including using more recent data and conducting data quality checks to advance the use of the AOC index to ensure better focus on anesthesia and perioperative care in global SOTA care.

References

1. Garimella V, Cellini C. Postoperative pain control. *Clinics in colon and rectal surgery* 2013; 26: 191–6.

2. Duthey B, Scholten W. Adequacy of opioid analgesic consumption at country, global, and regional levels in 2010, its relationship with development level, and changes compared with 2006. *Journal of Pain and Symptom Management* 2014; 47: 283–97.

3. Jayawardana S, Forman R, Johnston-Webber C et al. Global consumption of prescription opioid analgesics between 2009-2019: a country-level observational study. *EClinicalMedicine* 2021; 42: 101198.

4. Richards GC, Aronson JK, Mahtani KR, Heneghan C. Global, regional, and national consumption of controlled opioids: a cross-sectional study of 214 countries and non-metropolitan territories. *British journal of pain* 2022; 16: 34–40.

5. Ju C, Wei L, Man KKC et al. Global, regional, and national trends in opioid analgesic consumption from 2015 to 2019: a longitudinal study. *The Lancet. Public health* 2022; 7: e335–46.

6. Scholten WK, Christensen A-E, Olesen AE, Drewes AM. Quantifying the adequacy of opioid analgesic consumption globally: an updated method and early findings. *American Journal of Public Health* 2019; 109: 52–7.

7. Gan TJ. Poorly controlled postoperative pain: prevalence, consequences, and prevention. *Journal of pain research* 2017; 10: 2287–98.

8. Santhirapala V, Peden CJ, Meara JG et al. Towards high-quality peri-operative care: a global perspective. *Anaesthesia* 2020; 75 Suppl 1: e18–27.

9. Meara JG, Leather AJM, Hagander L et al. Global Surgery 2030: evidence and solutions for achieving health, welfare, and economic development. *The Lancet* 2015; 386: 569–624.

10. International Narcotics Control Board. *Report of the International Narcotics Control Board for 2017*. United Nations, 2018.

11. Vranken MJM, Mantel-Teeuwisse AK, Jünger S et al. Legal barriers in accessing opioid medicines: results of the ATOME quick scan of national legislation of eastern European countries. *Journal of Pain and Symptom Management* 2014; 48: 1135–44.

12. Soffin EM, Lee BH, Kumar KK, Wu CL. The prescription opioid crisis: role of the anaesthesiologist in reducing opioid use and misuse. *British Journal of Anaesthesia* 2019; 122: e198–208.

13. LeBrun DG, Chackungal S, Chao TE et al. Prioritizing essential surgery and safe anesthesia for the Post-2015 Development Agenda: operative capacities of 78 district hospitals in 7 low- and middle-income countries. *Surgery* 2014; 155: 365–73.

Figure Captions

Figure 1: Adequacy of prescription opioid consumption across A) multiple countries and territories, B) World Health Organization regions, and C) World Bank Income Groups. Adequacy is assessed for prescription opioid consumption. The adequacy levels were classified as adequate (AOC >100), moderate (<100 and >30), low (<30 and >10), very low (<10 and >3), and extremely low (<3).

A

Adequacy of Opioid Consumption (AOC)

- 0 to 3
- 3 to 10
- 10 to 30
- 30 to 100
- 100 or more
- Missing

B $F_{Welch}(5,72.11) = 4.43$, p = 0.001, $\widehat{\omega_p^2} = 0.10$, $CI_{95\%}$ [0.01, 0.18], $n_{obs} = 190$

$p_{adjusted} = 0.015$

$p_{adjusted} = 0.028$

$p_{adjusted} = 0.028$

$\widehat{\mu} = 1.53$

$\widehat{\mu} = 14.47$

$\widehat{\mu} = 1.82$

$\widehat{\mu} = 36.94$

$\widehat{\mu} = 1.79$

$\widehat{\mu} = 10.64$

AOC

AFR (n = 46) AMR (n = 36) EMR (n = 20) EUR (n = 50) SEAR (n = 12) WPR (n = 26)

WHO Regions

In favor of null: $\log_e(BF_{01}) = -4.99$, $r_{Cauchy}^{JZS} = 0.71$

Pairwise comparisons: **Games-Howell test**; Adjustment (p-value): **Holm**

C $F_{Welch}(3,95.76) = 16.58$, p = < 0.001, $\widehat{\omega_p^2} = 0.21$, $CI_{95\%}$ [0.11, 0.31], $n_{obs} = 190$

$p_{adjusted} \leq 0.001$

$p_{adjusted} \leq 0.001$

$p_{adjusted} \leq 0.001$

$p_{adjusted} \leq 0.001$

$p_{adjusted} = 0.006$

$\widehat{\mu} = 43.65$

$\widehat{\mu} = 0.28$

$\widehat{\mu} = 1.17$

$\widehat{\mu} = 3.32$

AOC

HIC (n = 58) LIC (n = 28) LMIC (n = 52) UMIC (n = 52)

World Bank Income Groups (2017)

In favor of null: $\log_e(BF_{01}) = -17.72$, $r_{Cauchy}^{JZS} = 0.71$

Pairwise comparisons: **Games-Howell test**; Adjustment (p-value): **Bonferroni**